BRAF and neoplasm: Specific tumor cells can rapidly adapt to the presence of BRAF/MEK inhibitors by turning on a feedback mechanism that can reestablish MEK/ERK signaling, which is often mediated through a receptor tyrosine kinase (RTK) signaling pathway (illustrated in Figure 2).